Gyre Therapeutics (NASDAQ:GYRE) Shares Down 6.9% – Here’s Why

Gyre Therapeutics, Inc. (NASDAQ:GYRE) was down 6.9% on Thursday . The company traded as low as $6.84 and last traded at $6.7780. Approximately 99,751 shares traded hands during mid-day trading, an increase of 12% from the average daily volume of 88,812 shares. The stock had previously closed at $7.28.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on GYRE shares. Zacks Research downgraded Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, March 16th. Wall Street Zen downgraded Gyre Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings downgraded Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday. Two equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $17.00.

Gyre Therapeutics Trading Down 6.4%

The firm has a market cap of $635.55 million, a price-to-earnings ratio of -72.77 and a beta of 2.03. The stock has a 50-day moving average of $7.43 and a 200-day moving average of $7.65.

Gyre Therapeutics (NASDAQ:GYRE) last released its quarterly earnings data on Thursday, March 12th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). Gyre Therapeutics had a negative net margin of 5.44% and a positive return on equity of 3.13%. The company had revenue of $37.20 million for the quarter, compared to analyst estimates of $36.30 million. As a group, research analysts expect that Gyre Therapeutics, Inc. will post -0.3 earnings per share for the current fiscal year.

Insider Transactions at Gyre Therapeutics

In related news, CEO Ying Luo sold 10,136 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $8.04, for a total transaction of $81,493.44. Following the completion of the transaction, the chief executive officer owned 2,565,226 shares in the company, valued at $20,624,417.04. The trade was a 0.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 10.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. State of Alaska Department of Revenue acquired a new position in Gyre Therapeutics during the 3rd quarter worth $38,000. Bank of America Corp DE boosted its position in Gyre Therapeutics by 28.8% during the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after acquiring an additional 1,402 shares during the period. JPMorgan Chase & Co. boosted its position in Gyre Therapeutics by 84.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after acquiring an additional 2,961 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Gyre Therapeutics by 77.8% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after acquiring an additional 3,244 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new position in Gyre Therapeutics during the 4th quarter worth $77,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.